Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All drugs

Nimacimab

Stage Phase 2Stale

Sponsor Skye Bioscience, Inc.

Route injection

Sources

registry, as of 2026-01-14Stale

https://clinicaltrials.gov/study/NCT06577090

Protocol section, NCT06577090 CBeyond, last update posted 2026-01-14

Studies

CBeyond

Registry NCT06577090

Phase Phase 2

Status Active, not recruiting

Enrollment 136

Start 2024-08-22

Primary completion 2026-11-20

Catalyst Primary completion. 2026-11-20Stale

Nimacimab injection

Nimacimab placebo injection

Semaglutide injection + Nimacimab injection 200 mg

Dose 200 mg

Semaglutide injection + Nimacimab placebo injection

Open-label 300 mg Nimacimab injection (study extension)

Dose 300 mg